Abbott Laboratories ABT
101.29
0.22
0.22%
as of 25 Sep
- Market cap
- $174.8B
- P/E
- 32.8×
Follow ABT
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Abbott Laboratories (ABT) Net income
Abbott Laboratories's net income for fiscal 2025 was $6.5B, down 51.3% from $13.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.4B. Over the past ten years it has ranged from $477.0M (fiscal 2017) to $13.4B (fiscal 2024); the current reading is higher than 73% of that period. Abbott Laboratories ranks 1st of 149 Medical Devices companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $6.5B | (51.32%) |
| FY2024 | $13.4B | 134.18% |
| FY2023 | $5.7B | (17.45%) |
| FY2022 | $6.9B | (1.95%) |
| FY2021 | $7.1B | 57.31% |
| FY2020 | $4.5B | 21.91% |
| FY2019 | $3.7B | 55.70% |
| FY2018 | $2.4B | 396.44% |
| FY2017 | $477.0M | (65.93%) |
| FY2016 | $1.4B | (68.35%) |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $928.0M | (13.83%) |
| Mar 2026 | $1.1B | (39.36%) |
| Dec 2025 | $1.8B | 8.03% |
| Sep 2025 | $1.6B | (7.59%) |
| 42 more quarters | Free account |
Against its own ten years
Low $477.0M
High $13.4B
Ten-year median
$4.5B
Current reading's percentile
73
Net income against peers
| Company | Net income |
|---|---|
| ABT Abbott Laboratories | $5.4B |
| MDT Medtronic PLC compare | $5.3B |
| SYK Stryker Corporation compare | $3.7B |
| BSX Boston Scientific Corporation compare | $3.7B |
| GEHC GE HealthCare Technologies Inc. compare | $2.1B |
| PHG Koninklijke Philips N.V. compare | $1.3B |
| EW Edwards Lifesciences Corporation compare | $1.0B |
| DXCM DexCom, Inc. compare | $999.7M |
| STE STERIS plc compare | $808.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ABT
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement